



Technology Available for License

Tolerizing Agent for Autoimmune, Inflammatory, and Allergic Reactions

Fusion protein is effective at extremely low doses to induce antigen-specific host tolerance in oral or nasal applications.

Tolerizing Agents

A new approach to developing highly virulent and antigen-specific tolerizing agents uses a mucosal targeting ligand fused to a specific antigen to induce host unresponsiveness solely to that antigen. The ligand protein can be fused to a broad range of antigens enabling tolerance to a number of autoimmune diseases, inflammatory diseases, and allergies. The fusion protein is capable of regulating peripheral tolerance subsequent to nasal or oral application (delivery).

Applications

Induce tolerance for applications such as:

- Autoimmune diseases
- Inflammatory Diseases
- Allergies
- Permits continuous treatment with biologicals. For example, tolerance has been demonstrated in mice challenged with ovalbumin or myelin proteins, the latter for treatment against multiple sclerosis.

Benefits

- Low dose required (500-fold greater effectiveness compared to conventional toleragens)
- Tolerance can be obtained, in some cases, with as few as one dose
- Induce antigen-specific tolerance avoiding global immune suppression
- Oral or nasal delivery
- Range of antigens can be fused to mucosal ligand delivery molecule to develop different toleragens to specific diseases

Technology Transfer and Development Status

A Patent is pending and research is ongoing.

Contact for licensing or further details

Nick Zelter, MSU Technology Transfer Officer, 406/994-7706, nzelter@montana.edu

To see all MSU technologies available for licensing go to:

<http://tto.montana.edu/technologies>